





















PatientID: HDR25

Okitobba 06, 2023

### Color Code

 HR: High-Level Resistance     PLR: Potential Low-Level Resistance  
 LR: Low-Level Resistance     IR: Intermediate Resistance  
 S: Susceptible

DRUG.CLASS	DRUG	RESISTANCE.PROFILE	DRMS.above.20.percent.prevalence
PI	ATV	 S	
	DRV	 S	
	FPV	 S	
	IDV	 S	
	LPV	 S	
	NFV	 S	
	SQV	 S	
	TPV	 S	
NRTI	ABC	 S	
	AZT	 S	
	D4T	 S	
	DDI	 S	
	FTC	 S	
	LMV	 S	
	TDF	 S	
NNRTI	DOR	 S	
	EFV	 S	
	ETR	 S	
	NVP	 S	
	RPV	 S	

## Appendix

### Drug abbreviations in full

DRUG.CLASS	ABBREVIATION	DRUG.NAME
PI	ATV	Atazanavir
	DRV	Darunavir
	FPV	Fosamprenavir
	IDV	Indinavir
	LPV	Lopinavir
	NFV	Nelfinavir
	SQV	Saquinavir
	TPV	Tipranavir
NRTI	ABC	Abacavir
	AZT	Azidothymidine
	DFT	Stavudine
	DDI	Didanosine
	FTC	Emtricitabine
	LMV	Lamivudine
	TDF	Tenofovir
NNRTI	DOR	Doravirine
	EFV	Efavirenz
	ETR	Etravirine
	NVP	Nevirapine
	RPV	Rilpivirine
INSTI	BIC	Bictegravir
	CAB	Cabotegravir
	DTG	Dolutegravir
	EVG	Elvitegravir
	RAL	Raltegravir

### Comments

DRUG.CLASS	COMMENTS
PI	
NRTI	
NNRTI	
INSTI	